- Home
- HOOK vs NERV Comparison
HOOK vs NERV Comparison
Compare HOOK & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOOK
- NERV
- Stock Information
- Founded
- HOOK 2011
- NERV 2007
- Country
- HOOK United States
- NERV United States
- Employees
- HOOK N/A
- NERV N/A
- Industry
- HOOK Biotechnology: Pharmaceutical Preparations
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- HOOK Health Care
- NERV Health Care
- Exchange
- HOOK Nasdaq
- NERV Nasdaq
- Market Cap
- HOOK 11.9M
- NERV 12.0M
- IPO Year
- HOOK 2019
- NERV 2014
- Fundamental
- Price
- HOOK $0.89
- NERV $1.91
- Analyst Decision
- HOOK Hold
- NERV Hold
- Analyst Count
- HOOK 3
- NERV 1
- Target Price
- HOOK $4.50
- NERV $5.00
- AVG Volume (30 Days)
- HOOK 155.2K
- NERV 21.0K
- Earning Date
- HOOK 08-11-2025
- NERV 08-12-2025
- Dividend Yield
- HOOK N/A
- NERV N/A
- EPS Growth
- HOOK N/A
- NERV N/A
- EPS
- HOOK N/A
- NERV 0.83
- Revenue
- HOOK $9,351,000.00
- NERV N/A
- Revenue This Year
- HOOK N/A
- NERV N/A
- Revenue Next Year
- HOOK N/A
- NERV N/A
- P/E Ratio
- HOOK N/A
- NERV $2.35
- Revenue Growth
- HOOK N/A
- NERV N/A
- 52 Week Low
- HOOK $0.72
- NERV $1.15
- 52 Week High
- HOOK $6.00
- NERV $3.06
- Technical
- Relative Strength Index (RSI)
- HOOK 19.78
- NERV 51.54
- Support Level
- HOOK $0.89
- NERV $1.87
- Resistance Level
- HOOK $0.95
- NERV $2.32
- Average True Range (ATR)
- HOOK 0.06
- NERV 0.15
- MACD
- HOOK -0.01
- NERV -0.01
- Stochastic Oscillator
- HOOK 7.11
- NERV 28.76
About HOOK HOOKIPA Pharma Inc.
HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.